Brigham and Women's Hospital

Dr. Frank J. Veith Joins the Board of Directors of ViTAA Medical Solutions

Retrieved on: 
Jeudi, février 29, 2024
Software, Research, General Health, Technology, Public Relations, Investor Relations, Clinical Trials, Science, Surgery, Biotechnology, Communications, Other Science, Health, Chin Na, Cleveland Clinic, University Medical Center, Harvard Medical School, Medical corps, Vascular disease, Vitaa, Brigham and Women's Hospital, Lung transplantation, Medicine, Management

ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.

Key Points: 
  • ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.
  • "We are honored to welcome Dr. Veith to our Board of Directors," said Mitchel Benovoy, CEO of ViTAA Medical Solutions.
  • Dr. Veith's addition to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies.
  • "I am honored and excited to join the ViTAA Board of Directors and contribute to their mission of transforming vascular care," said Dr. Veith.

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
Mercredi, mars 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Jeudi, février 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Point Foundation Welcomes New Board Members to Advance LGBTQ Empowerment

Retrieved on: 
Jeudi, janvier 18, 2024
Student, KPMG, LGBTQ, Brigham, Savage X Fenty, Internal medicine, Mentorship, Hospital, Point Foundation, Brigham and Women's Hospital, Management

LOS ANGELES, Jan. 18, 2024 /PRNewswire/ -- Point Foundation, the nation's leading scholarship-granting organization for LGBTQ college students, is thrilled to announce the appointment of new leaders to its boards.

Key Points: 
  • LOS ANGELES, Jan. 18, 2024 /PRNewswire/ -- Point Foundation, the nation's leading scholarship-granting organization for LGBTQ college students, is thrilled to announce the appointment of new leaders to its boards.
  • The new board members include:
    Carl Streed, Jr. – Associate Professor at the Boston University Chobanian & Avedisian School of Medicine.
  • Louis advocates for LGBTQ employees and improving the diversity, equity, and inclusion of KPMG as part of the LGBTQ employee resource group, pride@KPMG.
  • "As we navigate the political and social challenges to LGBTQ students seeking a post-secondary education in the years ahead of us, the insights and leadership of these new board members are essential to our mission of empowering LGBTQ students nationwide," said Jorge Valencia, executive director and CEO of Point Foundation.

Nabla Raises $24M in Series B to Fuel Expansion of its Ambient AI Assistant to Transform Care Delivery

Retrieved on: 
Vendredi, janvier 5, 2024
Public health, EHR, Hospital, API, Confidentiality, Language, STT, Brigham and Women's Hospital, Health, Informatics, Doctor of Philosophy, Heart, Health equity, Professor, LLM, AI, Privacy, Nabla, Traction, Series, Growth, Patient, Health informatics, Partner (business rank), Pharmaceutical industry

BOSTON, Jan. 5, 2024 /PRNewswire/ -- Nabla , the leading ambient AI assistant for practitioners, today announced the initial close of a $24M Series B funding round led by Cathay Innovation , with participation from ZEBOX Ventures .

Key Points: 
  • BOSTON, Jan. 5, 2024 /PRNewswire/ -- Nabla , the leading ambient AI assistant for practitioners, today announced the initial close of a $24M Series B funding round led by Cathay Innovation , with participation from ZEBOX Ventures .
  • This investment enables Nabla to boost expansion across U.S. healthcare systems and continue transforming the way providers deliver care with its ambient AI assistant.
  • Clinicians have deemed managing the electronic health record (EHR) the biggest stressor in patient care.
  • Available on mobile, desktop, and API, Nabla continually improves its user experience by applying feedback from its engaged clinician community.

ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer

Retrieved on: 
Mercredi, janvier 3, 2024
Associate, Ipsen, Hospital, Science, Partnership, Duvelisib, Biotechnology, Drug development, Research, Pathology, Acquisition, BWH, Brigham and Women's Hospital, Therapy, EZH2, Verastem Oncology, Hematology, Stony Brook University, PI3K, Kinetic, Patient, Harvard Medical School, AbbVie, Management

WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.

Key Points: 
  • WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.
  • "Dr. Kutok is a seasoned executive with the right credentials to guide ENSEM's science into the future," stated Shengfang Jin, Ph.D., President & Chief Executive Officer of ENSEM.
  • Dr. Kutok previously served as Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the company's scientific strategy, preclinical development, and translational science.
  • "I am thrilled to join the ENSEM team at this exciting time," stated Dr. Jeff Kutok, Chief Scientific Officer at ENSEM.

Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

Retrieved on: 
Mardi, décembre 19, 2023
Hospital, Woman, Ovarian cancer, Endometrioma, Dana–Farber Cancer Institute, MicroRNA, Brigham and Women's Hospital, MD, Doctor of Philosophy, Endometriosis, Assistant, Harvard Medical School, Gynaecology, Reproductive biology, Birth control

After a brief overview of the current treatment pathway for ovarian cancer and endometriosis, our panelists will provide an update on each of the company’s in-development products, including how each can close clinical gaps and improve health outcomes for women.

Key Points: 
  • After a brief overview of the current treatment pathway for ovarian cancer and endometriosis, our panelists will provide an update on each of the company’s in-development products, including how each can close clinical gaps and improve health outcomes for women.
  • Product updates will include upcoming milestones, pending publications, and future revenue potential for:
    The only commercially available ovarian cancer blood test for women diagnosed with an adnexal mass considered indeterminate or benign by initial clinical assessment.
  • A promising new blood test that combines Aspira’s proprietary protein biomarker technology with miRNAs licensed from the Dana Farber Cancer Institute.
  • The first protein biomarker test for the identification of ovarian endometriosis, including endometrioma.

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on: 
Mardi, décembre 12, 2023
Constellation, Entrepreneurship, Hospital, Genetic code, MIT, CMC, CRISPR, JD, PASTE, Brigham and Women's Hospital, DNA, MD, Doctor of Philosophy, Therapy, Investment, HR, Polaris Partners, Novo Nordisk, Novartis, Polaris, Patent, MorphoSys, Cas9, ARCH, ARCH Venture Partners, Gene expression, Bruker, Genetic heterogeneity, Gene, Merck, PGI, Genome, Enzyme, Fujifilm, Patient, GV, Intellia Therapeutics

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points: 
  • Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
  • “PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
  • “PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
  • Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care

Retrieved on: 
Mardi, décembre 19, 2023
Conference, National Cancer Institute, Alternative, Partnership, World Bank, Research, Chairperson, Dana–Farber Cancer Institute, White, Cancer Moonshot, Brigham and Women's Hospital, Congress, Society, Cancer, Health equity, AI, Nutrition, Future, Assistant, Face, Child, Patient, Bristol Myers Squibb, Foreign Policy, Policy, World Bank Group

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.

Key Points: 
  • With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
  • Hannah Adams, a pediatric cancer survivor, reminded the audience that "the most effective advocates put a face and a name to the child of cancer."
  • The Future of Cancer Care panel delved into the potential of AI, equity considerations, and global access.
  • The Burjeel Holdings Oncology Conference served as a powerful call to action, urging individuals to support research, advocate for patient-centered policies, and raise awareness.

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care

Retrieved on: 
Mardi, décembre 19, 2023
Conference, National Cancer Institute, Alternative, Partnership, World Bank, Research, Chairperson, Dana–Farber Cancer Institute, White, Cancer Moonshot, Brigham and Women's Hospital, Congress, Society, Cancer, Health equity, AI, Nutrition, Future, Assistant, Face, Child, Patient, Bristol Myers Squibb, Foreign Policy, Policy, World Bank Group

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.

Key Points: 
  • With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
  • Hannah Adams, a pediatric cancer survivor, reminded the audience that "the most effective advocates put a face and a name to the child of cancer."
  • The Future of Cancer Care panel delved into the potential of AI, equity considerations, and global access.
  • The Burjeel Holdings Oncology Conference served as a powerful call to action, urging individuals to support research, advocate for patient-centered policies, and raise awareness.